Gynecologic Cancer News

The FDA approved niraparib for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.

A cell-free DNA multicancer early detection test demonstrated an ability to predict cancer and the tissue of origin in individuals with clinical suspicion of cancer, according to results of the Circulating Cell-free Genome Atlas study presented at the virtual American Association for Cancer Research Annual Meeting.

Intratumoral mRNA-2416, a lipid nanoparticle therapeutic agent expressing the wild-type human OX40L, appeared safe among a cohort of patients with locally advanced, recurrent or metastatic solid tumors, according to results of a phase 1/2 first-in-human study presented at the virtual American Association for Cancer Research Annual Meeting.

The combination of pembrolizumab and GX-188E, a DNA vaccine targeting HPV types 16 and 18, conferred high response rates compared with pembrolizumab alone among a cohort of women with advanced, inoperable or metastatic cervical cancer, according to results of an interim analysis presented at the virtual American Association for Cancer Research Annual Meeting.

Women who received the HPV vaccine after surgical excision for high-grade cervical dysplasia had lower risk for recurrence than women who received placebo or surgery alone, according to results of a systemic review and meta-analysis presented at the virtual Society of Gynecologic Cancer Annual Meeting.

The US Oncology Network named Robert L. Coleman, MD, FACOG, FACS, its new chief scientific officer.

Female gynecologic oncologists who work in academic settings make significantly less money than their male peers, according to survey results presented at the virtual Society of Gynecologic Cancer Annual Meeting.

The FDA granted fast track designation to balstilimab for treatment of women with advanced cervical cancer.

The FDA granted priority review to pembrolizumab for treatment of adults and children with unresectable or metastatic solid tumors that have high tissue tumor mutational burden.